The IFOPA is pleased to share this press release from Regeneron Pharmaceuticals providing an update on the OPTIMA trial. Thank you to the 63 members of the FOP community who participated in this trial.
This press release does NOT mean that the drug being tested in this trial, garetosmab, is available for doctors to prescribe. This press release provides a first look at the trial results. Regeneron will report the full trial results to the U.S. Food and Drug Administration and then make decisions about its next steps.
Important Note: The OPTIMA clinical trial is active, but not currently recruiting, so it is not accepting any new patients.
Questions? If you participated in the OPTIMA trial, you should contact the principal investigator at your trial site. If you have another question about this press release or any of the FOP clinical trials, email [email protected]
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation
Garetosmab is the first and only treatment to demonstrate a dramatic reduction in both number and volume of abnormal bone lesions (heterotopic ossification, or HO lesions) in adults with FOP
Primary endpoint was met, showing a 90% or greater reduction in new HO lesions at 56 weeks, and garetosmab also led to a greater than 99% reduction in the total volume of new HO lesions
Based on these data and the safety profile, the Independent Data Monitoring Committee (IDMC) recommended those receiving placebo be transitioned to garetosmab as soon as possible; U.S. regulatory submission of garetosmab in adults planned for year-end 2025
TARRYTOWN, N.Y., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the primary endpoint was met in the Phase 3 OPTIMA trial investigating garetosmab in adults with fibrodysplasia ossificans progressiva (FOP). At 56 weeks, both doses of garetosmab, 3 mg/kg and 10 mg/kg, were highly efficacious in reducing the number of new bone lesions (heterotopic ossification, or HO lesions) as compared to placebo, demonstrating a 94% and 90% reduction, respectively. Garetosmab is a monoclonal antibody that neutralizes the Activin A protein, which Regeneron scientists discovered to be a critical protein in the development of HO lesions in people with FOP.
“Heterotopic ossification is a hallmark of FOP, a horrific disease in which muscles, tendons and ligaments are progressively replaced by bone, gradually incapacitating patients,” said Professor Richard Keen, Director of the Metabolic Bone Disease Centre, Royal National Orthopaedic Hospital, London, and global primary investigator of the OPTIMA trial. “The OPTIMA trial results clearly illustrate the potential of garetosmab to alter the disease and reduce new lesions that define this condition. Notably, garetosmab is the first and only investigational therapy to demonstrate a dramatic reduction in both the number and volume of abnormal bone lesions."
OPTIMA, a global, multi-center, randomized, double-blind, placebo-controlled trial, enrolled 63 people with FOP aged 18 years and older. Trial participants were randomized to intravenously receive either placebo, 3 mg/kg garetosmab, or 10 mg/kg garetosmab once every four weeks. Following this, participants could elect to extend their treatment through at least 84 weeks or discontinue treatment and enter into an observation-only arm.
In OPTIMA, the primary and key secondary endpoints were assessed at 56 weeks. As seen in the table below, the total number of new HO lesions was significantly reduced, which was further reaffirmed by the reduction in total new lesion volume.
See the full press release for a chart with more details about the trial endpoints.
At 56 weeks, there were no discontinuations among the garetosmab treatment arms, and there was one discontinuation in the placebo arm due to an ovarian cyst. There was a dose-dependent increase in skin and soft tissue infections (n=7, n=9, n=15 for the placebo, 3 mg/kg garetosmab, and 10 mg/kg garetosmab arms, respectively). There was no dose-dependent increase in epistaxis (n=5, n=10, n=4 for the placebo, 3 mg/kg garetosmab, and 10 mg/kg garetosmab arms, respectively); and there were no serious bleeding events. There was a decrease in musculoskeletal pain-related adverse events, similar in both garetosmab arms (n=14, n=6, n=4 for the placebo, 3 mg/kg garetosmab and 10 mg/kg garetosmab arms, respectively). Serious treatment-emergent adverse events occurred in 2 patients treated with placebo, 1 patient treated with 3 mg/kg garetosmab, and 2 patients treated with 10 mg/kg garetosmab. No deaths were reported in the trial.
"The success of the OPTIMA trial is a direct result of Regeneron’s relentless pursuit of science and use of proprietary technologies to improve the lives of people with debilitating and life-threatening diseases, no matter their prevalence,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. “Our research in FOP began decades ago – leading to the discovery of the role Activin A plays in driving this devastating disease, and now, a medicine with the potential to prevent the uncontrolled formation of new bone. We are thankful to the many patients, healthcare providers, and others who have been active partners on this journey, and we look forward to submitting garetosmab for evaluation by regulatory authorities as soon as possible.”
Based on these data and the safety profile, the Independent Data Monitoring Committee (IDMC) recommended those receiving placebo be transitioned to garetosmab as soon as possible. A U.S. regulatory submission for garetosmab to treat FOP is planned for year-end 2025, with global regulatory submissions slated for 2026. These data are also planned for future presentation and publication. A Phase 3 trial of garetosmab in adolescents and children with FOP, OPTIMA 2, is intended to begin next year.
The potential use of garetosmab for the treatment of FOP is investigational and has not been approved by any regulatory authority.
About the OPTIMA Clinical Trial
OPTIMA is a Phase 3, multi-center, multinational trial to assess the efficacy of garetosmab on the reduction of heterotopic bone formation, as well as its safety, tolerability, and pharmacokinetics, in patients with active fibrodysplasia ossificans progressiva (FOP).
The trial enrolled 63 patients aged 18 years and older who have any FOP-causing variant of type I Activin A receptor (ACVR1), exhibited FOP disease activity or progression of heterotopic ossification (HO) lesions, and had a cumulative analogue joint involvement (CAJIS) score at screening of ≤19. CAJIS is a clinician-assessed tool, with higher scores representing greater disease severity (scale: 0 to 30). Eligible participants were randomized to intravenously receive 3 mg/kg garetosmab, 10 mg/kg garetosmab, or placebo once every four weeks for 56 weeks. Following this, participants could elect to extend their treatment for at least 84 weeks or discontinue treatment and enter into an observation-only arm.
During the treatment period, efficacy was evaluated through whole body computed tomography (CT) scans for HO lesions; physician and patient assessment of flare-ups; utilization of the CAJIS scale to rate joint functionality; and observances of change in disease severity. Safety assessment includes reports of adverse events, measurement of vital signs, physical examination, and coagulation testing.
A Phase 3 trial of garetosmab in adolescents and children with FOP, OPTIMA 2, is planned to begin next year. For more information, visit the Regeneron clinical trials website, contact [email protected], or call +1 844-734-6643.
About Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia ossificans progressiva (FOP) is a relentless, progressive, ultra-rare genetic disorder in which muscles, tendons and ligaments are progressively replaced by bone, a process known as heterotopic ossification (HO). Approximately 900 people are diagnosed with FOP worldwide, with many others thought to remain undiagnosed or misdiagnosed.
HO of the jaw, spine, hip and rib cage can make it difficult to speak, eat, walk or breathe, leading to weight loss and escalating loss of mobility and skeletal deformity. People with FOP also experience episodic, localized inflammation known as "flare-ups," although HO may occur both silently as well as in association with symptoms. Most people with FOP are wheelchair bound by 30 years old and the median age of survival is approximately 56 years. Death often results from complications, such as pneumonia, heart failure and aspiration stemming from HO and loss of mobility in the chest, neck and jaw.
About Garetosmab
Regeneron has been engaged in FOP research for decades and helped to provide fundamental insights in the biology and natural history of the disease. Regeneron scientists discovered that Activin A plays a key role in FOP by driving HO, the main pathology of FOP. Garetosmab is a VelocImmune-derived fully-human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP.
In 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for garetosmab for the prevention of HO in patients with FOP. In the U.S. and European Union (EU), garetosmab has been granted Orphan Designation. Garetosmab is currently under clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.
